<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="38730e0b-146d-4b8f-b69e-797da8f231d9"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use FOSAPREPITANT FOR INJECTION safely and effectively. See full prescribing information for FOSAPREPITANT FOR INJECTION.<br/>
      <br/>FOSAPREPITANT for injection, for intravenous use<br/>Initial U.S. Approval: 2008</title>
   <effectiveTime value="20230714"/>
   <setId root="0e4ff71c-c0d1-4644-ab80-fd903ff86181"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079558168" root="1.3.6.1.4.1.519.1"/>
            <name>Hepalink USA Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="542977621"/>
                  <name>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="542977621"/>
                        <name>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="81952-911" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="81952-911" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="bcafb843-ff47-44da-8c9c-5689a5b00913"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20230726"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="81952-911" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>FOSAPREPITANT</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>FOSAPREPITANT</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator value="150" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="D35FM8T64X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FOSAPREPITANT DIMEGLUMINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1NF15YR6UY" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>APREPITANT</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="6L8OF9XRDC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FOSAPREPITANT</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="5.4" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="395" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator value="75" unit="mg"/>
                              <denominator value="5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="81952-911-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230714"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA212143" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230714"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="f2cacaaa-ba2e-470d-9ca0-edffe31f6951"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.</item>
                     <item>delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).</item>
                  </list>
               </text>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fosaprepitant for injection is a substance P/neurokinin-1 (NK<sub>1</sub>) receptor antagonist, indicated in adults, in combination with other antiemetic agents, for the prevention of <linkHtml href="#S1">(1)</linkHtml> :</paragraph>
                        <list listType="unordered">
                           <item>acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.</item>
                           <item>delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use <linkHtml href="#S1">(1)</linkHtml>
                           </content>
                        </paragraph>
                        <list listType="unordered">
                           <item>Fosaprepitant  has not been studied for treatment of established nausea and vomiting.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="04210169-095c-443a-b25f-a6045ce78330"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fosaprepitant has not been studied for the treatment of established nausea and vomiting.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="86730a58-d829-49a0-8c67-5fa59a3d4b49"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="underline">Recommended Dosage (<linkHtml href="#S2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>Administer fosaprepitant for injection as an intravenous infusion; complete the infusion approximately 30 minutes prior to chemotherapy<content styleCode="underline">.</content>​</item>
                           <item>Adults: 150 mg on Day 1.</item>
                           <item>Administer fosaprepitant for injection on Day 1 as an intravenous infusion over 20 to 30 minutes (adults).</item>
                           <item>See Full Prescribing Information for dosages of concomitant antiemetic(s). (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="658978db-3a97-4e27-ade6-fb1aa8675c1d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Prevention of Nausea and Vomiting Associated with HEC and MEC in Adult Patients</title>
                     <text>
                        <paragraph>The recommended dosage of fosaprepitant for injection, dexamethasone, and a 5-HT<sub>3</sub> antagonist in adults for the prevention of nausea and vomiting associated with administration of HEC or MEC is shown in <linkHtml href="http://Table%201">Table 1</linkHtml> or <linkHtml href="http://">Table 2</linkHtml>, respectively. Administer fosaprepitant for injection as an intravenous infusion on Day 1 over 20 to 30 minutes, completing the infusion approximately 30 minutes prior to chemotherapy.</paragraph>
                        <table ID="table1" width="75%">
                           <caption>Table 1 Recommended Adult Dosing for the Prevention of Nausea and Vomiting Associated with HEC</caption>
                           <colgroup>
                              <col width="23%" align="left" valign="top"/>
                              <col width="20%" align="center" valign="top"/>
                              <col width="19%" align="center" valign="top"/>
                              <col width="19%" align="center" valign="top"/>
                              <col width="19%" align="center" valign="top"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left"/>
                                 <th styleCode="Rrule" align="center">Day 1</th>
                                 <th styleCode="Rrule" align="center">Day 2</th>
                                 <th styleCode="Rrule" align="center">Day 3</th>
                                 <th styleCode="Rrule" align="center">Day 4</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <paragraph>Fosaprepitant </paragraph>
                                    <paragraph>for injection</paragraph>
                                 </td>
                                 <td styleCode="Rrule" align="center">150 mg intravenously over 20 to 30 minutes</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Dexamethasone<footnote ID="L3ea29790-dac7-4c60-9f8a-4154eb80d121">Administer dexamethasone 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. Also administer dexamethasone in the evenings on Days 3 and 4. A 50% dosage reduction of dexamethasone on Days 1 and 2 is recommended to account for a drug interaction with fosaprepitant<content styleCode="italics"> [see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">12 mg orally</td>
                                 <td styleCode="Rrule" align="center">8 mg orally</td>
                                 <td styleCode="Rrule" align="center">8 mg orally twice daily</td>
                                 <td styleCode="Rrule" align="center">8 mg orally twice daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">5-HT<sub>3</sub> antagonist</td>
                                 <td styleCode="Rrule" align="center">See selected 5-HT<sub>3</sub> antagonist prescribing information for the recommended dosage</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="table2" width="75%">
                           <caption>Table 2 Recommended Adult Dosing for the Prevention of Nausea and Vomiting Associated with MEC</caption>
                           <colgroup>
                              <col width="30%" align="left" valign="top"/>
                              <col width="70%" align="center" valign="top"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left"/>
                                 <th styleCode="Rrule" align="center">Day 1</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <paragraph>Fosaprepitant</paragraph>
                                    <paragraph>for injection</paragraph>
                                 </td>
                                 <td styleCode="Rrule" align="center">150 mg intravenously over 20 to 30 minutes</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Dexamethasone<footnote ID="t2f1">Administer dexamethasone 30 minutes prior to chemotherapy treatment on Day 1. A 50% dosage reduction of dexamethasone is recommended to account for a drug interaction with fosaprepitant  <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">12 mg orally</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">5-HT<sub>3</sub> antagonist</td>
                                 <td styleCode="Rrule" align="center">See selected 5-HT<sub>3</sub> antagonist prescribing information for the recommended dosage</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="L2d1599af-e982-4dc3-ab30-93802d3a840c">
                     <id root="eaa1156e-2e36-47ca-ad4c-00dd6fbb2d2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="5d78ebf7-e8fc-4da1-a87a-68d5e169e7e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation of Fosaprepitant for Injection</title>
                     <text>
                        <table width="75%">
                           <caption>Table 5 Preparation Instructions for Fosaprepitant for Injection (150 mg)</caption>
                           <colgroup>
                              <col width="10%" valign="top" align="left"/>
                              <col width="90%" valign="top" align="left"/>
                           </colgroup>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td colspan="2" align="left"/>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">Step 1</td>
                                 <td styleCode="Rrule" align="left">
                                    <paragraph>Aseptically inject 5 mL 0.9% Sodium Chloride Injection, USP into the vial. Assure that 0.9% Sodium Chloride Injection, USP is added to the vial along the vial wall in order to prevent foaming. Swirl the vial gently. Avoid shaking and jetting 0.9% Sodium Chloride Injection, USP into the vial.</paragraph>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Step 2</td>
                                 <td styleCode="Rrule" align="left">Aseptically prepare an infusion bag filled with 145 mL of 0.9% Sodium Chloride Injection, USP.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Step 3</td>
                                 <td styleCode="Rrule" align="left">Aseptically withdraw the entire volume from the vial and transfer it into the infusion bag containing 145 mL of 0.9% Sodium Chloride Injection, USP to yield a <content styleCode="bold">total</content> volume of 150 mL and a final concentration of 1 mg/mL.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Step 4</td>
                                 <td styleCode="Rrule" align="left">Gently invert the bag 2 to 3 times.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Step 5</td>
                                 <td styleCode="Rrule" align="left">
                                    <paragraph/>
                                    <paragraph>
                                       <content styleCode="underline">Adults</content>
                                       <br/>The entire volume of the prepared infusion bag (150 mL) should be administered.</paragraph>
                                    <paragraph/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Step 6</td>
                                 <td styleCode="Rrule" align="left">Before administration, inspect the bag for particulate matter and discoloration. Discard the bag if particulate and/or discoloration are observed.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Caution:</content> Do not mix or reconstitute fosaprepitant for injection with solutions for which physical and chemical compatibility have not been established. Fosaprepitant for injection is incompatible with any solutions containing divalent cations (e.g., Ca<sup>2+</sup>, Mg<sup>2+</sup>), including Lactated Ringer's Solution and Hartmann's Solution.</paragraph>
                     </text>
                     <effectiveTime value="20230726"/>
                     <component>
                        <section>
                           <id root="bd3016e4-8086-4785-9d0e-60088b56fa2a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage</content>
                              </paragraph>
                              <paragraph>The reconstituted final drug solution is stable for 24 hours at ambient room temperature [at or below 25°C (77°F)].</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="30f3e455-1001-40a9-8b0b-f3a5283fa444"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Fosaprepitant for injection: 150 mg fosaprepitant, white to off-white lyophilized powder in single-dose glass vial for reconstitution.</paragraph>
               </text>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fosaprepitant for injection: 150 mg fosaprepitant, lyophilized powder in single-dose vial for reconstitution. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="1f3bedb0-f5c1-4c9d-9b1e-968a6764fec0"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Fosaprepitant is contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>who are hypersensitive to any component of the product. Hypersensitivity reactions including anaphylactic reactions, flushing, erythema, and dyspnea have been reported <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>, <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.</item>
                     <item>taking pimozide. Inhibition of CYP3A4 by aprepitant, the active moiety, could result in elevated plasma concentrations of this drug, which is a CYP3A4 substrate, potentially causing serious or life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to any component of this drug. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>Concurrent use with pimozide. (<linkHtml href="#S4">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="7cd7291e-ebf2-4540-a925-2364b32ac59b"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">CYP3A4 Interactions:</content> Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4; see Full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of fosaprepitant and concomitant drugs. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions (including anaphylaxis and anaphylactic shock):</content> May occur during or soon after infusion. If symptoms occur, discontinue the drug. Do not reinitiate fosaprepitant if symptoms occur with previous use. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Infusion Site Reactions (including thrombophlebitis, necrosis, and vasculitis):</content> Majority of reactions reported in patients receiving vesicant chemotherapy. Avoid infusion into small veins. Discontinue infusion and administer treatment if a severe reaction develops. (<linkHtml href="#L3483343c-6c15-436d-af8e-684810f97ecd">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Warfarin (a CYP2C9 substrate):</content> Risk of decreased INR of prothrombin time; monitor INR in 2–week period, particularly at 7 to 10 days, following initiation of fosaprepitant. (<linkHtml href="#S5.3">5.4</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hormonal Contraceptives:</content> Efficacy of contraceptives may be reduced during and for 28 days following administration of fosaprepitant. Use effective alternative or back-up methods of contraception. (<linkHtml href="#S5.4">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="d7c1e59c-24bb-4259-a6f6-eee0ef55e0b6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1	Clinically Significant CYP3A4 Drug Interactions</title>
                     <text>
                        <paragraph>Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Use of fosaprepitant with other drugs that are CYP3A4 substrates, may result in increased plasma concentration of the concomitant drug.<list listType="unordered" styleCode="Circle">
                                 <item>Use of pimozide with fosaprepitant is contraindicated due to the risk of significantly increased plasma concentrations of pimozide, potentially resulting in prolongation of the QT interval, a known adverse reaction of pimozide <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]. </content>
                                 </item>
                              </list>
                           </item>
                           <item>Use of fosaprepitant with strong or moderate CYP3A4 inhibitors (e.g., ketoconazole, diltiazem) may increase plasma concentrations of aprepitant and result in an increased risk of adverse reactions related to fosaprepitant.</item>
                           <item>Use of fosaprepitant with strong CYP3A4 inducers (e.g., rifampin) may result in a reduction in aprepitant plasma concentrations and decreased efficacy of fosaprepitant.</item>
                        </list>
                        <paragraph>See <linkHtml href="#table5">Table 7</linkHtml> and <linkHtml href="#table6">Table 8</linkHtml> for a listing of potentially significant drug interactions <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>, <linkHtml href="#S7.2">7.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="5e11c84e-29cd-4409-9117-abea26dcf15f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2	Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, during or soon after infusion of fosaprepitant have occurred. Symptoms including flushing, erythema, dyspnea, hypotension and syncope have been reported <content styleCode="italics">[see <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>]</content>.<br/>Monitor patients during and after infusion. If hypersensitivity reactions occur, discontinue the infusion and administer appropriate medical therapy. Do not reinitiate fosaprepitant in patients who experience these symptoms with previous use <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="L3483343c-6c15-436d-af8e-684810f97ecd">
                     <id root="6c2374fc-ada8-49e9-b698-247bdba12764"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Infusion Site Reactions</title>
                     <text>
                        <paragraph>Infusion site reactions (ISRs) have been reported with the use of fosaprepitant for injection <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. The majority of severe ISRs, including thrombophlebitis and vasculitis, were reported with concomitant vesicant (anthracycline-based) chemotherapy administration, particularly when associated with extravasation. Necrosis was also reported in some patients with concomitant vesicant chemotherapy. Most ISRs occurred with the first, second or third exposure to single doses of fosaprepitant for injection and in some cases, reactions persisted for two weeks or longer. Treatment of severe ISRs consisted of medical, and in some cases surgical, intervention.</paragraph>
                        <paragraph>Avoid infusion of fosaprepitant for injection into small veins or through a butterfly catheter. If a severe ISR develops during infusion, discontinue the infusion and administer appropriate medical treatment.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="321ef53d-0407-4d0b-b71a-47b79a22c800"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Decrease in INR with Concomitant Warfarin</title>
                     <text>
                        <paragraph>Coadministration of fosaprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the International Normalized Ratio (INR) of prothrombin time <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant with each chemotherapy cycle <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="312cbaaf-6e4a-49ce-ada4-6e8b6770d5e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risk of Reduced Efficacy of Hormonal Contraceptives</title>
                     <text>
                        <paragraph>Upon coadministration with fosaprepitant, the efficacy of hormonal contraceptives may be reduced during administration of and for 28 days following the last dose of fosaprepitant <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Advise patients to use effective alternative or back-up methods of contraception during treatment with fosaprepitant and for 1 month following administration of fosaprepitant <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="L4746cc38-8139-44c3-b54c-5329d0d1a011">
               <id root="6d968386-f86e-4ed6-a9d5-3ed6a149cc10"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Infusion Site Reactions <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Most common adverse reactions (≥2%) are: fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity. (<linkHtml href="#S6.1">6.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact </content>
                           <content styleCode="bold">Hepalink USA Inc. </content>
                           <content styleCode="bold">at 1-888-355-1375</content>
                           <content styleCode="bold"> or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="69b28d86-8a63-48ac-ac52-e020ac96f815"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                        <paragraph>The overall safety of fosaprepitant for injection was evaluated in approximately 1600 adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="a5e37536-793c-4f00-b56f-fa7fddd63d0d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Adults for the Prevention of Nausea and Vomiting Associated with MEC </content>
                              </paragraph>
                              <paragraph>In an active-controlled clinical trial in patients receiving MEC, safety was evaluated in 504 patients receiving a single dose of fosaprepitant for injection in combination with ondansetron and dexamethasone (fosaprepitant regimen) compared to 497 patients receiving ondansetron and dexamethasone alone (standard therapy). The most common adverse reactions are listed in <linkHtml href="http://">Table 6</linkHtml>.</paragraph>
                              <table ID="table4" width="75%">
                                 <caption>Table 6 Most Common Adverse Reactions in Patients Receiving MEC<footnote ID="t4f1">Reported in ≥ 2% of patients treated with the fosaprepitant regimen and at a greater incidence than standard therapy.</footnote>
                                 </caption>
                                 <colgroup>
                                    <col width="40%" valign="top" align="left"/>
                                    <col width="30%" valign="top" align="center"/>
                                    <col width="30%" valign="top" align="center"/>
                                 </colgroup>
                                 <thead>
                                    <tr styleCode="First Last">
                                       <th styleCode="Lrule Rrule" align="left"/>
                                       <th styleCode="Rrule" align="center">Fosaprepitant for injection, ondansetron, and dexamethasone<footnote ID="t4f2">Fosaprepitant regimen</footnote>
                                          <br/>(N=504)</th>
                                       <th styleCode="Rrule" align="center">Ondansetron and dexamethasone<footnote ID="t4f3">Standard therapy</footnote>
                                          <br/>(N=497)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule First">
                                       <td styleCode="Lrule Rrule" align="left">fatigue</td>
                                       <td styleCode="Rrule" align="center">15%</td>
                                       <td styleCode="Rrule" align="center">13%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">diarrhea</td>
                                       <td styleCode="Rrule" align="center">13%</td>
                                       <td styleCode="Rrule" align="center">11%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">neutropenia</td>
                                       <td styleCode="Rrule" align="center">8%</td>
                                       <td styleCode="Rrule" align="center">7%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">asthenia</td>
                                       <td styleCode="Rrule" align="center">4%</td>
                                       <td styleCode="Rrule" align="center">3%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">anemia</td>
                                       <td styleCode="Rrule" align="center">3%</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">peripheral neuropathy</td>
                                       <td styleCode="Rrule" align="center">3%</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">leukopenia</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                       <td styleCode="Rrule" align="center">1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">dyspepsia</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                       <td styleCode="Rrule" align="center">1%</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule" align="left">urinary tract infection</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                       <td styleCode="Rrule" align="center">1%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule" align="left">pain in extremity</td>
                                       <td styleCode="Rrule" align="center">2%</td>
                                       <td styleCode="Rrule" align="center">1%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Infusion-site reactions were reported in 2.2% of patients treated with the fosaprepitant regimen compared to 0.6% of patients treated with standard therapy. The infusion-site reactions included: infusion-site pain (1.2%, 0.4%), injection-site irritation (0.2%, 0.0%), vessel puncture-site pain (0.2%, 0.0%), and infusion-site thrombophlebitis (0.6%, 0.0%), reported in the fosaprepitant regimen compared to standard therapy, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b6072c24-9379-4407-87c0-0ee7113fa1bc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adverse Reactions in Adults for the Prevention of Nausea and Vomiting Associated with HEC </content>
                              </paragraph>
                              <paragraph>In an active-controlled clinical study in patients receiving HEC, safety was evaluated for 1143 patients receiving a single dose of fosaprepitant for injection compared to 1169 patients receiving the 3-day regimen of oral aprepitant <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. The safety profile was generally similar to that seen in the MEC study with fosaprepitant and prior HEC studies with aprepitant. However, infusion-site reactions occurred at a higher incidence in patients in the fosaprepitant group (3.0%) compared to those in the aprepitant group (0.5%). The following additional infusion-site reactions occurred in the HEC study and were not reported in the MEC study described above: infusion-site erythema (0.5%, 0.1%), infusion-site pruritus (0.3%, 0.0%), and infusion-site induration (0.2%, 0.1%), reported in the fosaprepitant group compared to the aprepitant group, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section ID="L382522a7-b007-4c63-9008-5c3904b71b1c">
                           <id root="32cb4a10-d224-4329-88f4-9ffd0356ee62"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline"/>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                           <component>
                              <section ID="Le9cd749a-5a1d-48a9-aba9-9ab8ba98c1d3">
                                 <id root="d93cccc3-4fd5-46f1-be44-0ef27623f94c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Because fosaprepitant is converted to aprepitant, those adverse reactions associated with aprepitant might also be expected to occur with fosaprepitant for injection. See the full prescribing information for aprepitant capsules for complete safety information regarding studies performed with oral aprepitant.</paragraph>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="4e7707ba-c2a0-4329-84a0-4810e3edbc42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of fosaprepitant/aprepitant. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> pruritus, rash, urticaria, Stevens-Johnson syndrome/toxic epidermal necrolysis <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune system disorders:</content> hypersensitivity reactions including anaphylaxis and anaphylactic shock <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders:</content> ifosfamide-induced neurotoxicity reported after fosaprepitant and ifosfamide coadministration.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="bb4ac28b-ebc0-4794-b088-c4144a7d9d1f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230703"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>See Full Prescribing Information for a list of clinically significant drug interactions. (<linkHtml href="#S4">4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>,  <linkHtml href="#S5.3">5.4</linkHtml>, <linkHtml href="#S5.4">5.5</linkHtml>, <linkHtml href="#S7.1">7.1</linkHtml>, <linkHtml href="#S7.2">7.2</linkHtml>)</paragraph>
                        <paragraph/>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="e5d7098a-82ff-4568-a1b4-16508fea9724"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Effect of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs</title>
                     <text>
                        <paragraph>When administered intravenously, fosaprepitant, a prodrug of aprepitant, is converted to aprepitant within 30 minutes. Therefore, drug interactions following administration of fosaprepitant for injection are likely to occur with drugs that interact with oral aprepitant.</paragraph>
                        <paragraph>Fosaprepitant, given as a single 150-mg dose, is a weak inhibitor of CYP3A4, and the weak inhibition of CYP3A4 continues for 2 days after single dose administration. Single dose fosaprepitant does not induce CYP3A4. Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9 <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                        <paragraph>Some substrates of CYP3A4 are contraindicated with fosaprepitant <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>. Dosage adjustment of some CYP3A4 and CYP2C9 substrates may be warranted, as shown in <linkHtml href="#ID_table%205">Table 7</linkHtml>.</paragraph>
                        <table ID="table5" width="76%">
                           <caption>Table 7 Effects of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs</caption>
                           <colgroup>
                              <col width="20%" align="left" valign="top"/>
                              <col width="80%" align="left" valign="top"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">CYP3A4 Substrates</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Pimozide</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Increased pimozide exposure</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Fosaprepitant is contraindicated <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Benzodiazepines</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Monitor for benzodiazepine-related adverse reactions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Dexamethasone</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Increased dexamethasone exposure <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Reduce the dose of oral dexamethasone by approximately 50% <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Methylprednisolone</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Increased methylprednisolone exposure <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Reduce the dose of oral methylprednisolone by approximately 50% on Days 1 and 2 for patients receiving HEC and on Day 1 for patients receiving MEC.<br/>Reduce the dose of intravenous methylprednisolone by 25% on Days 1 and 2 for patients receiving HEC and on Day 1 for patients receiving MEC.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Chemotherapeutic agents that are metabolized by CYP3A4</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Increased exposure of the chemotherapeutic agent may increase the risk of adverse reactions <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">
                                    <content styleCode="underline">Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Monitor for chemotherapeutic-related adverse reactions.</item>
                                    </list>
                                    <content styleCode="underline">Etoposide, vinorelbine, paclitaxel, and docetaxel</content>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>No dosage adjustment needed.</item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Hormonal Contraceptives</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Decreased hormonal exposure during administration of and for 28 days after administration of the last dose of fosaprepitant <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>, and <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Effective alternative or back-up methods of contraception (such as condoms and spermicides) should be used during treatment with fosaprepitant and for 1 month following administration of fosaprepitant.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">birth control pills, skin patches, implants, and certain IUDs</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">CYP2C9 Substrates</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">Warfarin</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Decreased warfarin exposure and decreased prothrombin time (INR) <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">In patients on chronic warfarin therapy, monitor the prothrombin time (INR) in the 2-week period, particularly at 7 to 10 days, following administration of fosaprepitant with each chemotherapy cycle.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">Other</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="italics">5-HT<sub>3</sub> Antagonists</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">No change in the exposure of the 5-HT<sub>3</sub> antagonist <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">No dosage adjustment needed</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">ondansetron, granisetron, dolasetron</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="4b3942c8-c143-4e5d-ac82-201159048dfd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2	Effect of Other Drugs on the Pharmacokinetics of Fosaprepitant/Aprepitant</title>
                     <text>
                        <paragraph>Aprepitant is a CYP3A4 substrate <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]. </content>Co-administration of fosaprepitant with drugs that are inhibitors or inducers of CYP3A4 may result in increased or decreased plasma concentrations of aprepitant, respectively, as shown in <linkHtml href="http://Table 8">Table 8</linkHtml>.</paragraph>
                        <table ID="table6" width="75%">
                           <caption>Table 8 Effects of Other Drugs on Pharmacokinetics of Fosaprepitant/Aprepitant</caption>
                           <colgroup>
                              <col width="20%" align="left" valign="top"/>
                              <col width="80%" align="left" valign="top"/>
                           </colgroup>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">Moderate to Strong CYP3A4 Inhibitors</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Significantly increased exposure of aprepitant may increase the risk of adverse reactions associated with fosaprepitant <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Avoid concomitant use of fosaprepitant</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">
                                    <content styleCode="underline">Moderate inhibitor:</content>
                                    <br/>diltiazem</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left"/>
                                 <td styleCode="Rrule" align="left">
                                    <content styleCode="underline">Strong inhibitors: </content>
                                    <br/>ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2" align="left">
                                    <content styleCode="bold">Strong CYP3A4 Inducers</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Clinical Impact</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Substantially decreased exposure of aprepitant in patients chronically taking a strong CYP3A4 inducer may decrease the efficacy of fosaprepitant <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Intervention</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">Avoid concomitant use of fosaprepitant</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">
                                    <content styleCode="italics">Examples</content>
                                 </td>
                                 <td styleCode="Rrule" align="left">rifampin, carbamazepine, phenytoin</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="895fe327-eb18-4910-8849-3666fa996b16"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230703"/>
               <component>
                  <section ID="S8.1">
                     <id root="6c1f991e-577e-4f78-a723-95216e550aae"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="4a0985c1-64dd-47e0-9d67-c3827312fc89"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk. In animal reproduction studies, no adverse developmental effects were observed in rats or rabbits exposed during the period of organogenesis to systemic drug levels (AUC) approximately equivalent to the exposure at the recommended human dose (RHD) of 150 mg <content styleCode="italics">[see <linkHtml href="#data">Data</linkHtml>]</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="a668892f-2f9e-4ac5-88da-ab2de5499488"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                           <component>
                              <section>
                                 <id root="93d701c5-cef2-4a22-af8b-7a1951f530ac"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In embryofetal development studies in rats and rabbits, aprepitant was administered during the period of organogenesis at oral doses up to 1000 mg/kg twice daily (rats) and up to the maximum tolerated dose of 25 mg/kg/day (rabbits). No embryofetal lethality or malformations were observed at any dose level in either species. The exposures (AUC) in pregnant rats at 1000 mg/kg twice daily and in pregnant rabbits at 25 mg/kg/day were approximately equivalent to the exposure at the RHD of 150 mg. Aprepitant crosses the placenta in rats and rabbits.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="41a65fe3-bd4a-472a-af01-c9f4778cfcf4"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2	Lactation</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="59f0ce4d-c6b4-4563-b813-c2639e0a8038"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production. Aprepitant is present in rat milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for fosaprepitant and any potential adverse effects on the breastfed infant from fosaprepitant or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="8d04f182-4cee-4145-bcd8-9699b8afedc7"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3	Females and Males of Reproductive Potential</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="2bc1f72c-992c-4fcb-ba44-95e4cfbe4ae1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                              <paragraph>Upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced. Advise females of reproductive potential using hormonal contraceptives to use an effective alternative or back-up non-hormonal contraceptive (such as condoms and spermicides) during treatment with fosaprepitant and for 1 month following the last dose <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>, <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="b65be0e9-d6cf-4094-9c0c-3ac08b6f1e44"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of fosaprepitant for the prevention of nausea and vomiting associated with HEC or MEC have not been established in patients less than 6 months of age</paragraph>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section ID="L896db604-af1a-410d-9816-a0d925d4c35c">
                           <id root="2549cfa5-071b-483f-a07e-cc35d28291cc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                                 <br/>In juvenile dogs treated with fosaprepitant, changes in reproductive organs were observed. In juvenile rats treated with aprepitant, slight changes in sexual maturation were observed without an effect on reproduction. No effects on neurobehavior, sensory and motor function, or learning and memory were observed in rats.</paragraph>
                              <paragraph>In a toxicity study in juvenile dogs treated with fosaprepitant from postnatal day 14 (equivalent to a newborn human) to day 42 (approximately equivalent to a 2 year old human), decreased testicular weight and Leydig cell size were seen in the males at 6 mg/kg/day and increased uterine weight, hypertrophy of the uterus and cervix, and edema of vaginal tissues were seen in females from 4 mg/kg/day. A study was also conducted in young rats to evaluate the effects of aprepitant on growth and on neurobehavioral and sexual development. Rats were treated at oral doses up to the maximum feasible dose of 1000 mg/kg twice daily from the early postnatal period (Postnatal Day 10 (equivalent to a newborn human) through Postnatal Day 58 (approximately equivalent to a 15 year old human)). Slight changes in the onset of sexual maturation were observed in female and male rats; however, there were no effects on mating, fertility, embryonic-fetal survival, or histomorphology of the reproductive organs. There were no effects in neurobehavioral tests of sensory function, motor function, and learning and memory.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="5a8ed154-e465-4945-8fa0-d8be7b37fc8d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 1649 adult cancer patients treated with intravenous fosaprepitant in HEC and MEC clinical studies, 27% were aged 65 and over, while 5% were aged 75 and over. Other reported clinical experience with fosaprepitant has not identified differences in responses between elderly and younger patients. In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="cb17644a-0b85-4c18-8531-22c567eb37c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6	Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>The pharmacokinetics of aprepitant in patients with mild and moderate hepatic impairment were similar to those of healthy subjects with normal hepatic function. No dosage adjustment is necessary for patients with mild to moderate hepatic impairment (Child-Pugh score 5 to 9). There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9). Therefore, additional monitoring for adverse reactions in these patients may be warranted when fosaprepitant is administered <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="586ea425-63fb-4321-8572-601d8bcb1ef2"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>There is no specific information on the treatment of overdosage with fosaprepitant or aprepitant.</paragraph>
                  <paragraph>In the event of overdose, fosaprepitant should be discontinued and general supportive treatment and monitoring should be provided. Because of the antiemetic activity of fosaprepitant, drug-induced emesis may not be effective in cases of fosaprepitant overdosage.</paragraph>
                  <paragraph>Aprepitant is not removed by hemodialysis.</paragraph>
               </text>
               <effectiveTime value="20230703"/>
            </section>
         </component>
         <component>
            <section ID="L8fa7c2c0-a195-4557-b1f0-9f3f1e6bdd6a">
               <id root="f21d149f-47b3-4374-8eed-55cac0121f70"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fosaprepitant for injection is a sterile, lyophilized formulation containing fosaprepitant dimeglumine, a prodrug of aprepitant, a substance P/neurokinin-1 (NK<sub>1</sub>) receptor antagonist, an antiemetic agent, chemically described as 1-Deoxy-1-(methylamino)-D-glucitol[3-[[(2<content styleCode="italics">R</content>,3<content styleCode="italics">S</content>)-2-[(1<content styleCode="italics">R</content>)-1-[3,5- bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1<content styleCode="italics">H</content>-1,2,4- triazol-1-yl]phosphonate (2:1) (salt).<br/>Its empirical formula is C<sub>23</sub>H<sub>22</sub>F<sub>7</sub>N<sub>4</sub>O<sub>6</sub>P ⋅ 2(C<sub>7</sub>H<sub>17</sub>NO<sub>5</sub>) and its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Lcb89beb7-b836-4e35-b80f-f8ad8bbab613"/>
                  </paragraph>
                  <paragraph>Fosaprepitant dimeglumine is a white to off-white amorphous powder with a molecular weight of 1004.83. It is freely soluble in water.</paragraph>
                  <paragraph>Each vial of fosaprepitant for injection for administration as an intravenous infusion contains 150 mg of fosaprepitant (equivalent to 245.3 mg of fosaprepitant dimeglumine) and the following inactive ingredients: edetate disodium (5.4 mg), polysorbate 80 (75 mg), lactose monohydrate (395 mg), sodium hydroxide and/or hydrochloric acid (for pH adjustment).</paragraph>
               </text>
               <effectiveTime value="20230703"/>
               <component>
                  <observationMedia ID="Lcb89beb7-b836-4e35-b80f-f8ad8bbab613">
                     <text>chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="m01-chemical structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="ce4cf646-eb60-412c-bf26-beb6f9375133"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230703"/>
               <component>
                  <section ID="S12.1">
                     <id root="aee010ab-f0d4-470e-99b1-9dbf08a257ca"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant.</paragraph>
                        <paragraph>Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK<sub>1</sub>) receptors. Aprepitant has little or no affinity for serotonin (5-HT<sub>3</sub>), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK<sub>1</sub> receptors. Animal and human studies have shown that aprepitant augments the antiemetic activity of the 5-HT<sub>3</sub>-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="04a32004-0507-47e9-92d8-062abf625283"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="fe698f77-caa7-4ac9-b94b-6eab0bd4dc32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>In a randomized, double-blind, positive-controlled, thorough QTc study, a single 200-mg dose of fosaprepitant (approximately 1.3 times the recommended dose) had no effect on the QTc interval.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="755dbd8b-d487-444f-8165-603b297fa355"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="e0d0fe97-69fa-4cb1-976b-d1f16e413eb9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Aprepitant after Fosaprepitant Administration</content>
                              </paragraph>
                              <paragraph>Following administration of a single intravenous 150-mg dose of fosaprepitant, a prodrug of aprepitant administered as a 20-minute infusion to healthy subjects, the mean AUC<sub>0-∞</sub> of aprepitant was 37.4 (± 14.8) mcg∙hr/mL and the mean maximal aprepitant concentration (C<sub>max</sub>) was 4.2 (± 1.2) mcg/mL. Plasma concentrations of fosaprepitant are below the limits of quantification (10 ng/mL) within 30 minutes of the completion of infusion.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f95b1841-5200-44c8-8df8-cb5aba4e7da4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Aprepitant is greater than 95% bound to plasma proteins. The mean apparent volume of distribution at steady state (Vd<sub>ss</sub>) was approximately 70 L in humans.</paragraph>
                              <paragraph>Aprepitant crosses the blood brain barrier in humans <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="2a9443ce-07eb-444d-a86f-9c78c73cd485"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                           <component>
                              <section>
                                 <id root="7364d2f0-c036-4e8a-8b3b-ecb7a13cc303"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Fosaprepitant is converted to aprepitant in <content styleCode="italics">in vitro</content> incubations with human liver preparations and in S9 preparations from multiple other human tissues including kidney, lung and ileum. Thus, it appears that the conversion of fosaprepitant to aprepitant can occur in multiple extrahepatic tissues in addition to the liver.</paragraph>
                                    <paragraph>Aprepitant undergoes extensive metabolism. <content styleCode="italics">In vitro</content> studies using human liver microsomes indicate that aprepitant is metabolized primarily by CYP3A4 with minor metabolism by CYP1A2 and CYP2C19. Metabolism is largely via oxidation at the morpholine ring and its side chains. No metabolism by CYP2D6, CYP2C9, or CYP2E1 was detected.</paragraph>
                                    <paragraph>In healthy young adults, aprepitant accounts for approximately 24% of the radioactivity in plasma over 72 hours following a single oral 300-mg dose of [<sup>14</sup>C]-aprepitant, indicating a substantial presence of metabolites in the plasma. Seven metabolites of aprepitant, which are only weakly active, have been identified in human plasma.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="fb5dacfc-be42-44ea-8085-2c3e5b02c736"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following administration of a single intravenous 100-mg dose of [<sup>14</sup>C]-fosaprepitant to healthy subjects, 57% of the radioactivity was recovered in urine and 45% in feces.</paragraph>
                                    <paragraph>Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. The apparent terminal half-life ranged from approximately 9 to 13 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b1922d60-5291-4370-ab46-567119e48936"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                           <component>
                              <section>
                                 <id root="f22f2659-7efb-4896-95d4-9d56e82538a3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age: Geriatric Population</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                                 <component>
                                    <section ID="L37c0982f-777d-4cd6-9f6f-369fd0ac10ee">
                                       <id root="348d2bc3-ef9d-42fc-aad4-344ad567a380"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Following oral administration of a single 125-mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 through 5, the AUC<sub>0-24hr</sub> of aprepitant was 21% higher on Day 1 and 36% higher on Day 5 in elderly (65 years and older) relative to younger adults. The C<sub>max</sub> was 10% higher on Day 1 and 24% higher on Day 5 in elderly relative to younger adults. These differences are not considered clinically meaningful<content styleCode="italics"> [see Use in Specific Populations(8.5)]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="32ce26ca-3a2b-4a9f-9b04-0e39b98f3576"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Sex</content>
                                    </paragraph>
                                    <paragraph>Following oral administration of a single dose of aprepitant, ranging from 40 mg to 375 mg, the AUC<sub>0-24hr</sub> and C<sub>max</sub> are 9% and 17% higher in females as compared with males. The half-life of aprepitant is approximately 25% lower in females as compared with males and T<sub>max</sub> occurs at approximately the same time. These differences are not considered clinically meaningful. </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="85541292-ac44-4f70-8d7c-fe31132f53e6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Race/Ethnicity</content>
                                    </paragraph>
                                    <paragraph>Following oral administration of a single dose of aprepitant, ranging from 40 mg to 375 mg, the AUC<sub>0-24hr</sub> and C<sub>max</sub> are approximately 27% and 19% higher in Hispanics as compared with Caucasians. The AUC<sub>0-24hr</sub> and C<sub>max</sub> were 74% and 47% higher in Asians as compared to Caucasians. There was no difference in AUC<sub>0-24hr</sub> or C<sub>max</sub> between Caucasians and Blacks. These differences are not considered clinically meaningful. </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="c37e7cf8-3738-4b98-ac5b-5b1e582bbb4b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>A single 240-mg oral dose of aprepitant was administered to patients with severe renal impairment (creatinine clearance less than 30 mL/min/1.73 m<sup>2</sup> as measured by 24-hour urinary creatinine clearance) and to patients with end stage renal disease (ESRD) requiring hemodialysis.</paragraph>
                                    <paragraph>In patients with severe renal impairment, the AUC<sub>0-∞ </sub>of total aprepitant (unbound and protein bound) decreased by 21% and C<sub>max</sub> decreased by 32%, relative to healthy subjects (creatinine clearance greater than 80 mL/min estimated by Cockcroft-Gault method). In patients with ESRD undergoing hemodialysis, the AUC<sub>0-∞ </sub>of total aprepitant decreased by 42% and C<sub>max</sub> decreased by 32%. Due to modest decreases in protein binding of aprepitant in patients with renal disease, the AUC of pharmacologically active unbound drug was not significantly affected in patients with renal impairment compared with healthy subjects. Hemodialysis conducted 4 or 48 hours after dosing had no significant effect on the pharmacokinetics of aprepitant; less than 0.2% of the dose was recovered in the dialysate.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="aef649d9-7ec4-417f-87e9-68ec12079cc3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Fosaprepitant is metabolized in various extrahepatic tissues; therefore hepatic impairment is not expected to alter the conversion of fosaprepitant to aprepitant.</paragraph>
                                    <paragraph>Following administration of a single 125-mg oral dose of aprepitant on Day 1 and 80 mg once daily on Days 2 and 3 to patients with mild hepatic impairment (Child-Pugh score 5 to 6), the AUC<sub>0-24hr</sub> of aprepitant was 11% lower on Day 1 and 36% lower on Day 3, as compared with healthy subjects given the same regimen. In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), the AUC<sub>0-24hr</sub> of aprepitant was 10% higher on Day 1 and 18% higher on Day 3, as compared with healthy subjects given the same regimen. These differences in AUC<sub>0-24hr</sub> are not considered clinically meaningful. There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh score greater than 9) <content styleCode="italics">[see <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]</content>.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="bd3cba84-190d-4080-92f7-d2a177fcb950"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Body Mass Index (BMI)</content>
                                    </paragraph>
                                    <paragraph>For every 5 kg/m<sup>2</sup> increase in BMI, AUC<sub>0-24hr</sub> and C<sub>max</sub> of aprepitant decrease by 9% and 10%. BMI of subjects in the analysis ranged from 18 kg/m<sup>2</sup> to 36 kg/m<sup>2</sup>. This change is not considered clinically meaningful.</paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                           <component>
                              <section ID="Lf006c74a-050b-4d53-9fc0-0758e2d07a13">
                                 <id root="d5c7f3a0-f9a0-4f75-9603-d58219f1a38e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="30808051-9325-44b9-8662-930e94b169f9"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions Studies</content>
                              </paragraph>
                              <paragraph>Fosaprepitant, given as a single 150-mg dose, is a weak inhibitor of CYP3A4, with no evidence of inhibition or induction of CYP3A4 observed on Day 4. The weak inhibition of CYP3A4 continues for 2 days after single dose administration of fosaprepitant. Aprepitant is a substrate, an inhibitor, and an inducer of CYP3A4. Aprepitant is also an inducer of CYP2C9.</paragraph>
                              <paragraph>Fosaprepitant or aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                           <component>
                              <section>
                                 <id root="bf599fd3-7076-4cce-9e07-419e72c2b5c5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Effects of Fosaprepitant/Aprepitant on the Pharmacokinetics of Other Drugs</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                                 <component>
                                    <section>
                                       <id root="33e4a282-f249-442d-affb-a35490939309"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">CYP3A4 Substrates</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                       <component>
                                          <section>
                                             <id root="fa4f15cf-ef9e-47b1-a05c-789648784d13"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Midazolam:</content> Fosaprepitant 150 mg administered as a single intravenous dose on Day 1 increased the AUC<sub>0-∞</sub> of midazolam by approximately 1.8-fold on Day 1 and had no effect on Day 4 when midazolam was coadministered as a single oral dose of 2 mg on Days 1 and 4 <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="ddf8f3c4-cc31-4fc9-8f66-cf8104876d6a"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Corticosteroids:</content>
                                                </paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                             <component>
                                                <section>
                                                   <id root="8ea91206-176c-4e7e-a9e4-c26c3c30f66f"/>
                                                   <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                                   <text>
                                                      <paragraph>
                                                         <content styleCode="italics">Dexamethasone:</content> Fosaprepitant administered as a single 150 mg intravenous dose on Day 1 increased the AUC<sub>0-24hr</sub> of dexamethasone, administered as a single 8-mg oral dose on Days 1, 2, and 3, by approximately 2-fold on Days 1 and 2 <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>, <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                                   </text>
                                                   <effectiveTime value="20230703"/>
                                                </section>
                                             </component>
                                             <component>
                                                <section>
                                                   <id root="7cb14fb5-4285-4d77-b6fb-c2a83776fc21"/>
                                                   <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                                   <text>
                                                      <paragraph>
                                                         <content styleCode="italics">Methylprednisolone:</content> When oral aprepitant as a 3-day regimen (125-mg/80-mg/80-mg) was administered with intravenous methylprednisolone 125 mg on Day 1 and oral methylprednisolone 40 mg on Days 2 and 3, the AUC of methylprednisolone was increased by 1.34-fold on Day 1 and by 2.5-fold on Day 3 <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                                   </text>
                                                   <effectiveTime value="20230703"/>
                                                </section>
                                             </component>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="cb3814d1-7c08-438b-8266-bb688481cda2"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Chemotherapeutic agents:</content>
                                                </paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                             <component>
                                                <section>
                                                   <id root="b6573fcc-d038-4fc2-b302-8a9569a04d79"/>
                                                   <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                                   <text>
                                                      <paragraph>
                                                         <content styleCode="italics">Docetaxel:</content> In a pharmacokinetic study, oral aprepitant administered as a 3-day regimen (125-mg/80-mg/80-mg) did not influence the pharmacokinetics of docetaxel.</paragraph>
                                                   </text>
                                                   <effectiveTime value="20230703"/>
                                                </section>
                                             </component>
                                             <component>
                                                <section>
                                                   <id root="0f3b949d-f9c8-4b7d-82bc-b3d58e4ac635"/>
                                                   <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                                   <text>
                                                      <paragraph>
                                                         <content styleCode="italics">Vinorelbine:</content> In a pharmacokinetic study, oral aprepitant administered as a 3-day regimen (125-mg/80-mg/80-mg) did not influence the pharmacokinetics of vinorelbine to a clinically significant degree.</paragraph>
                                                   </text>
                                                   <effectiveTime value="20230703"/>
                                                </section>
                                             </component>
                                             <component>
                                                <section>
                                                   <id root="f286c804-14cf-4a7e-b786-d990ba8c7f31"/>
                                                   <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                                   <text>
                                                      <paragraph>
                                                         <content styleCode="italics">Oral contraceptives: </content>When oral aprepitant was administered as a 3-day regimen (125-mg/80-mg/80-mg) with ondansetron and dexamethasone, and coadministered with an oral contraceptive containing ethinyl estradiol and norethindrone, the trough concentrations of both ethinyl estradiol and norethindrone were reduced by as much as 64% for 3 weeks post-treatment <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                                   </text>
                                                   <effectiveTime value="20230703"/>
                                                </section>
                                             </component>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="c537b404-708f-48c8-8189-bd00c44563e2"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">CYP2C9 substrates (Warfarin, Tolbutamide):</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                       <component>
                                          <section>
                                             <id root="74550c00-111e-4c35-8a55-8aac7bf7e110"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Warfarin: </content>A single 125-mg dose of oral aprepitant was administered on Day 1 and 80 mg/day on Days 2 and 3 to subjects who were stabilized on chronic warfarin therapy. Although there was no effect of oral aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-) warfarin trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with oral aprepitant <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="d4545a1b-3949-472f-b4c9-ce472049c259"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">Tolbutamide: </content>Oral aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was administered prior to the administration of the 3-day regimen of oral aprepitant and on Days 4, 8, and 15. This effect was not considered clinically important.</paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="8d220cdc-ebe1-40fe-a8b0-d587e0ad1c6c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Other Drugs</content>
                                          </paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                       <component>
                                          <section>
                                             <id root="0a09ab24-ddb5-40e2-a89d-06e754299f0f"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">P-glycoprotein substrates: </content>Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of oral aprepitant with digoxin in a clinical drug interaction study.</paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                          </section>
                                       </component>
                                       <component>
                                          <section>
                                             <id root="d7dbfd57-6548-47ef-be48-633c9e538ed4"/>
                                             <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                             <text>
                                                <paragraph>
                                                   <content styleCode="italics">5-HT<sub>3 </sub>antagonists: </content>In clinical drug interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).</paragraph>
                                             </text>
                                             <effectiveTime value="20230703"/>
                                          </section>
                                       </component>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section ID="Lcc587cfc-b4c5-4de2-87e0-79e08e8b5f0f">
                                 <id root="fa54770b-f53e-4bac-ac6c-b801d3795a6b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Effect of Other Drugs on the Pharmacokinetics of Fosaprepitant/Aprepitant</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230703"/>
                                 <component>
                                    <section ID="Ld2e07639-fb4c-4335-b986-f42a9fd02e2e">
                                       <id root="c62c0948-c16b-4e3e-977d-4f485830f8a4"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Rifampin:</content> When a single 375-mg dose of oral aprepitant was administered on Day 9 of a 14-day regimen of 600 mg/day of rifampin, a strong CYP3A4 inducer, the AUC of aprepitant decreased approximately 11-fold and the mean terminal half-life decreased approximately 3-fold <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="Lbc1ad629-c245-438d-99a2-49686ef05c24">
                                       <id root="8ec2dd38-9702-4755-a0ba-bb23f375658c"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Ketoconazole:</content> When a single 125-mg dose of oral aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold<content styleCode="italics"> [see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="L5953b6f1-5f1c-47e3-9cf4-2418c8ce4f5b">
                                       <id root="0eae7516-cde6-4cef-a27a-45a0ac7eb4c6"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Diltiazem:</content> In a study in 10 patients with mild to moderate hypertension, administration of 100 mg of fosaprepitant as an intravenous infusion with 120 mg of diltiazem, a moderate CYP3A4 inhibitor administered three times daily, resulted in a 1.5-fold increase in the aprepitant AUC and a 1.4-fold increase in the diltiazem AUC.</paragraph>
                                          <paragraph>When fosaprepitant was administered with diltiazem, the mean maximum decrease in diastolic blood pressure was significantly greater than that observed with diltiazem alone [24.3 ± 10.2 mm Hg with fosaprepitant versus 15.6 ± 4.1 mm Hg without fosaprepitant]. The mean maximum decrease in systolic blood pressure was also greater after co-administration of diltiazem with fosaprepitant than administration of diltiazem alone [29.5 ± 7.9 mm Hg with fosaprepitant versus 23.8 ± 4.8 mm Hg without fosaprepitant]. Co-administration of fosaprepitant and diltiazem; however, did not result in any additional clinically significant changes in heart rate or PR interval, beyond those changes observed with diltiazem alone <content styleCode="italics">[see <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]</content>.</paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section ID="L9b4d6a88-846c-41d7-b128-d3457baf15e0">
                                       <id root="6eee1bf7-c542-42b5-965e-09460f6a2229"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Paroxetine:</content> Coadministration of once daily doses of oral aprepitant 170 mg, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and C<sub>max</sub> by approximately 20% of both aprepitant and paroxetine. This effect was not considered clinically important.</paragraph>
                                       </text>
                                       <effectiveTime value="20230703"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="8e5c44a0-eda5-4025-ab85-1e5c85138f5b"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230703"/>
               <component>
                  <section ID="S13.1">
                     <id root="ce0767bd-1e77-4c21-ae54-9087bc12b06a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="76319c67-b745-4b83-bf06-87c4f45b4025"/>
                           <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Carcinogenicity studies were conducted in Sprague-Dawley rats and in CD-1 mice for 2 years. In the rat carcinogenicity studies, animals were treated with oral doses ranging from 0.05 to 1000 mg/kg twice daily. The highest dose produced systemic exposures to aprepitant approximately equivalent to (female rats) or less than (male rats) the adult human exposure at the RHD of 150 mg. Treatment with aprepitant at doses of 5 to 1000 mg/kg twice daily caused an increase in the incidences of thyroid follicular cell adenomas and carcinomas in male rats. In female rats, it produced hepatocellular adenomas at 5 to 1000 mg/kg twice daily and hepatocellular carcinomas and thyroid follicular cell adenomas at 125 to 1000 mg/kg twice daily. In the mouse carcinogenicity studies, the animals were treated with oral doses ranging from 2.5 to 2000 mg/kg/day. The highest dose produced a systemic exposure approximately 2 times the adult human exposure at the RHD of 150 mg. Treatment with aprepitant produced skin fibrosarcomas at 125 and 500 mg/kg/day doses in male mice. Carcinogenicity studies were not conducted with fosaprepitant.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="051ca127-53b4-4fc7-9a11-41e7898e3bca"/>
                           <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Aprepitant and fosaprepitant were not genotoxic in the Ames test, the human lymphoblastoid cell (TK6) mutagenesis test, the rat hepatocyte DNA strand break test, the Chinese hamster ovary (CHO) cell chromosome aberration test and the mouse micronucleus test.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="83b04008-4a9d-4e61-91b9-f5f7c14bb2fb"/>
                           <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Fosaprepitant, when administered intravenously, is rapidly converted to aprepitant. In the fertility studies conducted with fosaprepitant and aprepitant, the highest systemic exposures to aprepitant were obtained following oral administration of aprepitant. Oral aprepitant did not affect the fertility or general reproductive performance of male or female rats at doses up to the maximum feasible dose of 1000 mg/kg twice daily (providing exposure in male rats lower than the exposure at the recommended adult human dose of 150 mg and exposure in female rats approximately equivalent to the adult human exposure).</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="4a73ebb5-060d-40a0-b8b8-a93a4747f8b6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20230703"/>
               <component>
                  <section ID="S14.1">
                     <id root="3ea3f917-dc7c-46e4-8dc6-057feb600b7c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Prevention of Nausea and Vomiting Associated with HEC in Adults</title>
                     <text>
                        <paragraph>In a randomized, parallel, double-blind, active-controlled study, fosaprepitant for injection 150 mg as a single intravenous infusion (N=1147) was compared to a 3-day oral aprepitant regimen (N=1175) in patients receiving a HEC regimen that included cisplatin (≥70 mg/m<sup>2</sup>). All patients in both groups received dexamethasone and ondansetron (see <linkHtml href="#table7">Table 11</linkHtml>). Patient demographics were similar between the two treatment groups. Of the total 2322 patients, 63% were men, 56% White, 26% Asian, 3% American Indian/Alaska Native, 2% Black, 13% Multi-Racial, and 33% Hispanic/Latino ethnicity. Patient ages ranged from 19 to 86 years of age, with a mean age of 56 years. Other concomitant chemotherapy agents commonly administered were fluorouracil (17%), gemcitabine (16%), paclitaxel (15%), and etoposide (12%).</paragraph>
                        <table ID="table7" width="75%">
                           <caption>Table 11 Treatment Regimens in Adult HEC Trial<footnote ID="t7f1">Fosaprepitant for injection placebo, aprepitant capsules placebo and dexamethasone placebo (in the evenings on Days 3 and 4) were used to maintain blinding.</footnote>
                           </caption>
                           <colgroup>
                              <col width="30%" align="left" valign="top"/>
                              <col width="20%" align="center" valign="top"/>
                              <col width="13%" align="center" valign="top"/>
                              <col width="17%" align="center" valign="top"/>
                              <col width="20%" align="center" valign="top"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left"/>
                                 <th styleCode="Rrule" align="center">Day 1</th>
                                 <th styleCode="Rrule" align="center">Day 2</th>
                                 <th styleCode="Rrule" align="center">Day 3</th>
                                 <th styleCode="Rrule" align="center">Day 4</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">Fosaprepitant Regimen</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">
                                    <paragraph>Fosaprepitant  </paragraph>
                                    <paragraph>for injection</paragraph>
                                 </td>
                                 <td styleCode="Rrule" align="center">150 mg intravenously over 20 to 30 minutes approximately 30 minutes prior to chemotherapy</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Oral dexamethasone<footnote ID="t7f2">Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. Dexamethasone was also administered in the evenings on Days 3 and 4. The 12 mg dose of dexamethasone on Day 1 and the 8 mg once daily dose on Day 2 reflects a dosage adjustment to account for a drug interaction with the fosaprepitant for injection regimen <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">12 mg</td>
                                 <td styleCode="Rrule" align="center">8 mg</td>
                                 <td styleCode="Rrule" align="center">8 mg twice daily</td>
                                 <td styleCode="Rrule" align="center">8 mg twice daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Ondansetron</td>
                                 <td styleCode="Rrule" align="center">Ondansetron<footnote ID="t7f3">Ondansetron 32 mg intravenous was used in the clinical trials of fosaprepitant/aprepitant. Although this dose was used in clinical trials, this is no longer the currently recommended dose. Refer to the ondansetron prescribing information for the current recommended dose.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Oral Aprepitant Regimen</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Aprepitant capsules</td>
                                 <td styleCode="Rrule" align="center">125 mg</td>
                                 <td styleCode="Rrule" align="center">80 mg</td>
                                 <td styleCode="Rrule" align="center">80 mg</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Oral dexamethasone<footnote ID="t7f4">Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1 and in the morning on Days 2 through 4. The 12 mg dose of dexamethasone on Day 1 and the 8 mg once daily dose on Days 2 through 4 reflects a dosage adjustment to account for a drug interaction with the oral aprepitant regimen <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">12 mg</td>
                                 <td styleCode="Rrule" align="center">8 mg</td>
                                 <td styleCode="Rrule" align="center">8 mg</td>
                                 <td styleCode="Rrule" align="center">8 mg</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Ondansetron</td>
                                 <td styleCode="Rrule" align="center">Ondansetron<footnoteRef IDREF="t7f3"/>
                                 </td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The efficacy of fosaprepitant for injection was evaluated based on the primary and secondary endpoints listed in <linkHtml href="#table 12">Table 12</linkHtml> and was shown to be non-inferior to that of the 3-day oral aprepitant regimen with regard to complete response in each of the evaluated phases. The pre-specified non-inferiority margin for complete response in the overall phase was 7%. The pre-specified non-inferiority margin for complete response in the delayed phase was 7.3%. The pre-specified non-inferiority margin for no vomiting in the overall phase was 8.2%.</paragraph>
                        <table ID="table8" width="75%">
                           <caption>Table 12 Percent of Adult Patients Receiving HEC Responding by Treatment Group and Phase — Cycle 1</caption>
                           <colgroup>
                              <col width="27%" align="left" valign="middle"/>
                              <col width="27%" align="center" valign="middle"/>
                              <col width="25%" align="center" valign="middle"/>
                              <col width="21%" align="center" valign="middle"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left" valign="top">ENDPOINTS</th>
                                 <th styleCode="Rrule" align="center" valign="top">Fosaprepitant  for Injection Regimen<br/>(N = 1106)<footnote ID="t8f1">N: Number of patients included in the primary analysis of complete response.</footnote>
                                    <br/>%</th>
                                 <th styleCode="Rrule" align="center" valign="top">Oral Aprepitant Regimen<br/>(N = 1134)<footnoteRef IDREF="t8f1"/>
                                    <br/>%</th>
                                 <th styleCode="Rrule" align="center" valign="top">Difference<footnote ID="t8f2">Difference and Confidence interval (CI) were calculated using the method proposed by Miettinen and Nurminen and adjusted for Gender.</footnote>
                                    <br/>(95% CI)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">PRIMARY ENDPOINT</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Complete Response<footnote ID="t8f3">Complete Response = no vomiting and no use of rescue therapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Overall<footnote ID="t8f4">Overall = 0 to 120 hours post-initiation of cisplatin chemotherapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">71.9</td>
                                 <td styleCode="Rrule" align="center">72.3</td>
                                 <td styleCode="Rrule" align="center">-0.4 (-4.1, 3.3)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">SECONDARY ENDPOINTS</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Complete Response<footnoteRef IDREF="t8f3"/>
                                 </td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">  Delayed phase<footnote ID="t8f5">Delayed phase = 25 to 120 hours post-initiation of cisplatin chemotherapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">74.3</td>
                                 <td styleCode="Rrule" align="center">74.2</td>
                                 <td styleCode="Rrule" align="center">0.1 (-3.5, 3.7)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">No Vomiting</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  Overall<footnoteRef IDREF="t8f4"/>
                                 </td>
                                 <td styleCode="Rrule" align="center">72.9</td>
                                 <td styleCode="Rrule" align="center">74.6</td>
                                 <td styleCode="Rrule" align="center">-1.7 (-5.3, 2.0)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="3140285d-f78b-4ef9-9927-e96e5db1adb2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Prevention of Nausea and Vomiting Associated with MEC in Adults</title>
                     <text>
                        <paragraph>In a randomized, parallel, double-blind, active comparator-controlled study, fosaprepitant for injection 150 mg as a single intravenous infusion (N=502) in combination with ondansetron and dexamethasone (fosaprepitant regimen) was compared with ondansetron and dexamethasone alone (standard therapy) (N=498) (see <linkHtml href="http://table 9">Table 13</linkHtml>) in patients receiving a MEC regimen. Patient demographics were similar between the two treatment groups. Of the total 1,000 patients included in the efficacy analysis, 41% were men, 84% White, 4% Asian, 1% American Indian/Alaska Native, 2% Black, 10% Multi-Racial, and 19% Hispanic/Latino ethnicity. Patient ages ranged from 23 to 88 years of age, with a mean age of 60 years. The most commonly administered MEC chemotherapeutic agents were carboplatin (51%), oxaliplatin (24%), and cyclophosphamide (12%).</paragraph>
                        <table ID="table9" width="75%">
                           <caption>Table 13 Treatment Regimens in Adult MEC Trial<footnote ID="t9f1">Fosaprepitant for injection placebo and dexamethasone placebo (on Day 1) were used to maintain blinding.</footnote>
                           </caption>
                           <colgroup>
                              <col width="40%" align="left" valign="top"/>
                              <col width="30%" align="center" valign="top"/>
                              <col width="15%" align="center" valign="top"/>
                              <col width="15%" align="center" valign="top"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left"/>
                                 <th styleCode="Rrule" align="center">Day 1</th>
                                 <th styleCode="Rrule" align="center">Day 2</th>
                                 <th styleCode="Rrule" align="center">Day 3</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">Fosaprepitant Regimen</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Fosaprepitant for injection</td>
                                 <td styleCode="Rrule" align="center">150 mg intravenously over 20 to 30 minutes approximately 30 minutes prior to chemotherapy</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Oral Dexamethasone<footnote ID="t9f2">Dexamethasone was administered 30 minutes prior to chemotherapy treatment on Day 1. The 12 mg dose reflects a dosage adjustment to account for a drug interaction with the fosaprepitant for injection regimen <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                                    </footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">12 mg</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Oral Ondansetron<footnote ID="t9f3">The first ondansetron dose was administered 30 to 60 minutes prior to chemotherapy treatment on Day 1 and the second dose was administered 8 hours after first ondansetron dose.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">8 mg for 2 doses</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Standard Therapy</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left" valign="middle">Oral Dexamethasone</td>
                                 <td styleCode="Rrule" align="center">20 mg</td>
                                 <td styleCode="Rrule" align="center">none</td>
                                 <td styleCode="Rrule" align="center">none</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">Oral Ondansetron<footnoteRef IDREF="t9f3"/>
                                 </td>
                                 <td styleCode="Rrule" align="center">8 mg for 2 doses</td>
                                 <td styleCode="Rrule" align="center">8 mg twice daily</td>
                                 <td styleCode="Rrule" align="center">8 mg twice daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The primary endpoint was complete response (defined as no vomiting and no rescue therapy) in the delayed phase (25 to 120 hours) of chemotherapy-induced nausea and vomiting. The results by treatment group are shown in <linkHtml href="#table 14">Table 14</linkHtml>.</paragraph>
                        <table ID="table10" width="75%">
                           <caption>Table 14 Percent of Adult Patients Receiving MEC Responding by Treatment Group</caption>
                           <colgroup>
                              <col width="23%" align="left" valign="middle"/>
                              <col width="23%" align="center" valign="middle"/>
                              <col width="19%" align="center" valign="middle"/>
                              <col width="16%" align="center" valign="middle"/>
                              <col width="19%" align="center" valign="middle"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="First Last">
                                 <th styleCode="Lrule Rrule" align="left" valign="top">ENDPOINTS</th>
                                 <th styleCode="Rrule" align="center" valign="top">Fosaprepitant for Injection Regimen<br/>(N = 502)<footnote ID="t10f1">N: Number of patients included in the intention to treat population.</footnote>
                                    <br/>%</th>
                                 <th styleCode="Rrule" align="center" valign="top">Standard Therapy Regimen<br/>(N = 498)<footnoteRef IDREF="t10f1"/>
                                    <br/>%</th>
                                 <th styleCode="Rrule" align="center" valign="top">P-Value</th>
                                 <th styleCode="Rrule" align="center" valign="top">Treatment Difference<br/>(95% CI)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td styleCode="Lrule Rrule" align="left">PRIMARY ENDPOINT</td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="left">Complete Response<footnote ID="t10f2">Complete Response = no vomiting and no use of rescue therapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                                 <td styleCode="Rrule" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" align="left">  Delayed phase<footnote ID="t10f3">Delayed phase = 25 to 120 hours post-initiation of chemotherapy.</footnote>
                                 </td>
                                 <td styleCode="Rrule" align="center">78.9</td>
                                 <td styleCode="Rrule" align="center">68.5</td>
                                 <td styleCode="Rrule" align="center">&lt;0.001</td>
                                 <td styleCode="Rrule" align="center">10.4 (5.1, 15.9)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="fec92326-327b-4879-9a07-ed9e67616081"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>No. 911 — Single-dose glass vial containing 150 mg of fosaprepitant as a white to off-white lyophilized powder for reconstitution. Supplied as follows:</paragraph>
                  <paragraph>
                     <content>NDC 81952-911-01                         </content>
                     <content>1 vial per carton.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230703"/>
               <component>
                  <section>
                     <id root="20fcc9f1-13ec-4f30-a5a6-b90340e01ff0"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Storage</content>
                        </paragraph>
                        <paragraph>Fosaprepitant for injection vials must be refrigerated, store at 2°C-8°C (36°F-46°F).</paragraph>
                        <paragraph>The reconstituted final drug solution is stable for 24 hours at ambient room temperature [at or below 25°C (77°F)].</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="1e971d52-3e45-4873-a8b0-3685960e9c9d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20230703"/>
               <component>
                  <section>
                     <id root="c9d71b77-abe5-4c62-a10b-fd46a2e814b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity </content>
                        </paragraph>
                        <paragraph>Advise patients that hypersensitivity reactions, including anaphylaxis and anaphylactic shock, have been reported in patients taking fosaprepitant. Advise patients to seek immediate medical attention if they experience signs or symptoms of a hypersensitivity reaction, such as hives, rash and itching, skin peeling or sores, flushing, difficulty in breathing or swallowing, or dizziness, rapid or weak heartbeat or feeling faint <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section ID="L93c52252-02de-40cf-b64e-2bf1b068fdcb">
                     <id root="c0df10d4-978f-4a04-a78f-c388efe9ca1f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion Site Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients to seek medical attention if they experience new or worsening signs or symptoms of an infusion site reaction, such as erythema, edema, pain, necrosis, vasculitis, or thrombophlebitis at or near the infusion site<content styleCode="italics"> [see <linkHtml href="#L3483343c-6c15-436d-af8e-684810f97ecd">Warnings and Precautions (5.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="4e5a7a43-cd8b-4a68-b0a6-f70c8b5c6975"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Advise patients to discuss all medications they are taking, including other prescription, non-prescription medication or herbal products <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230703"/>
                     <component>
                        <section>
                           <id root="ab1a1d41-f78b-4542-a119-949e57030577"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Warfarin:</content> Instruct patients on chronic warfarin therapy to follow instructions from their healthcare provider regarding blood draws to monitor their INR during the 2-week period, particularly at 7 to 10 days, following initiation of fosaprepitant with each chemotherapy cycle<content styleCode="italics"> [see <linkHtml href="#S5.3">Warnings and Precautions (5.4)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d972a9fd-13b7-49c7-902e-f6156acd3978"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Hormonal Contraceptives:</content> Advise patients that administration of fosaprepitant may reduce the efficacy of hormonal contraceptives. Instruct patients to use effective alternative or back-up methods of contraception (such as condoms and spermicides) during treatment with fosaprepitant and for 1 month following administration of fosaprepitant <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.5)</linkHtml>, <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20230703"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="4933ef1e-35e5-4eed-974a-aa03da6812b8"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by:<br/>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.<br/>Lianyungang, Jiangsu 222062 China</paragraph>
                  <paragraph>
                     <br/>Distributed by:<br/>Hepalink USA Inc.<br/>Langhorne, PA19047-1885</paragraph>
                  <paragraph>
                     <content>Toll Free: 1-888-355-1375</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230703"/>
            </section>
         </component>
         <component>
            <section ID="i4i_patient_package_insert_id_569421d6-479a-4d2a-b5d2-bc4ab617515f">
               <id root="3375ff9d-88cc-425d-9a87-bc8d1eccf819"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <colgroup>
                        <col width="50%" align="left" valign="top"/>
                        <col width="50%" align="left" valign="top"/>
                     </colgroup>
                     <tfoot>
                        <tr styleCode="First Last">
                           <td align="left">This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right">Revised: 6/2023       </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule First">
                           <td styleCode="Lrule Rrule" colspan="2" align="center">
                              <paragraph>Patient Information<br/>Fosaprepitant for Injection<br/>(fosaprepitant)<br/>for injection</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>Read this Patient Information before you start receiving fosaprepitant for injection and each time you are scheduled to receive fosaprepitant for injection. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">What is fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>Fosaprepitant for injection is a prescription medicine used with other medicines that treat nausea and vomiting in patients 18 years of age and older to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Fosaprepitant for injection is not used to treat nausea and vomiting that you already have.</item>
                                 <item>It is not known if fosaprepitant for injection is safe and effective in children less than 6 months of age.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">Who should not receive fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not receive fosaprepitant for injection if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to fosaprepitant, aprepitant, or any of the ingredients in fosaprepitant for injection. See the end of this leaflet for a complete list of the ingredients in fosaprepitant for injection.</item>
                                 <item>are taking pimozide (ORAP<sup>®</sup>)</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">What should I tell my healthcare provider before receiving fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Before receiving fosaprepitant for injection, tell your healthcare provider if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if fosaprepitant for injection can harm your unborn baby.<list listType="unordered" styleCode="Circle">
                                       <item>Women who use birth control medicines containing hormones to prevent pregnancy (birth control pills, skin patches, implants, and certain IUDs) should also use a backup method of birth control that does not contain hormones, such as condoms and spermicides, during treatment with fosaprepitant for injection and for 1 month after receiving fosaprepitant for injection.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if fosaprepitant for injection passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive fosaprepitant for injection.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Fosaprepitant  for injection may affect the way other medicines work, and other medicines may affect the way fosaprepitant for injection works, causing serious side effects.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">How will I receive fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Adults 18 years of age and older:</content>
                              </paragraph>
                              <paragraph>Fosaprepitant for injection will be given on Day 1 of chemotherapy treatment. It will be given to you by intravenous (IV) infusion in your vein about 50 to 60 minutes before you start your chemotherapy treatment.</paragraph>
                              <paragraph/>
                              <paragraph>If you take the blood thinner medicine warfarin sodium (COUMADIN<sup>®</sup>, JANTOVEN<sup>®</sup>), your healthcare provider may do blood tests after you receive fosaprepitant for injection to check your blood clotting.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Fosaprepitant  for injection may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Serious allergic reactions.</content> Allergic reactions can happen with fosaprepitant for injection and may be serious. Tell your doctor or nurse right away if you have hives, rash, itching, flushing or redness of your face or skin, trouble breathing or swallowing, dizziness, a rapid or weak heartbeat, or you feel faint during or soon after you receive fosaprepitant for injection, as you may need emergency medical care.</item>
                                 <item>Severe skin reactions, which may include rash, skin peeling, or sores, may occur.</item>
                                 <item>Infusion site reactions (ISR) at or near the infusion site have happened with fosaprepitant for injection.<br/>Most severe ISR have happened with a certain type of chemotherapy medicine that can burn or blister your skin (vesicant) with side effects, including pain, swelling and redness. Death of skin tissue (necrosis) has happened in some people getting this type of chemotherapy medicine. Most ISR can happen with the first, second, or third dose and some can last up to 2 weeks or longer. Tell your healthcare provider right away if you get any infusion site side effects.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">In adults, the most common side effects of fosaprepitant for injection include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>tiredness</item>
                                 <item>diarrhea</item>
                                 <item>low white blood cell and red blood cell counts</item>
                                 <item>weakness</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" align="left">
                              <list listType="unordered" styleCode="Disc">
                                 <item>feeling weak or numb in your arms and legs</item>
                                 <item>painful, difficult, or changes in your digestion (dyspepsia)</item>
                                 <item>urinary tract infection</item>
                                 <item>pain in your arms and legs</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of fosaprepitant for injection. For more information ask your healthcare provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of fosaprepitant for injection.</content>
                              </paragraph>
                              <paragraph>If you would like more information about fosaprepitant for injection, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about fosaprepitant for injection that is written for health professionals. For more information about fosaprepitant for injection call 1-888-355-1375.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule" colspan="2" align="left">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in fosaprepitant for injection?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content> fosaprepitant</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> edetate disodium, polysorbate 80, lactose monohydrate, sodium hydroxide and/or hydrochloric acid (for pH adjustment)</paragraph>
                              <paragraph/>
                              <paragraph>
                                 <content styleCode="italics">Pediatric use information is approved for Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s Emend (fosaprepitant) for injection. However, due to Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.</content>
                              </paragraph>
                              <paragraph/>
                              <paragraph>Manufactured by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Lianyungang, Jiangsu 222062 China<br/>Distributed by: Hepalink USA Inc., Langhorne PA19047-1885, Toll Free:1-888-355-1375.</paragraph>
                              <paragraph>The brands listed in the above sections “Who should not receive fosaprepitant for injection?” and “How will I receive fosaprepitant for injection?” are the registered trademarks of their respective owners.</paragraph>
                              <paragraph/>
                              <paragraph/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
               </text>
               <effectiveTime value="20230703"/>
            </section>
         </component>
         <component>
            <section ID="L2d67f13a-4846-4db6-b38e-5ae3dd4ac774">
               <id root="50995a0c-9366-4db0-aee2-d0adacfd0006"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 150 mg Vial Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 81952-911-01</paragraph>
                  <paragraph>
                     <content styleCode="bold">Fosaprepitant </content>
                     <br/>
                     <content styleCode="bold">for Injection</content>
                     <br/>
                     <content styleCode="bold">150mg per vial</content>
                  </paragraph>
                  <paragraph>
                     <br/>Reconstitute with 5 mL of 0.9%<br/>Sodium Chloride for injection</paragraph>
                  <paragraph>STERILE LYOPHILIZED POWDER FOR<br/>INTRAVENOUS USE ONLY AFTER<br/>RECONSTITUTION AND DILUTION</paragraph>
                  <paragraph>DO NOT USE WITH SOLUTIONS<br/>CONTAINING DIVALENT CATIONS ( e.g.,<br/>Ca<sup>2+</sup>, Mg<sup>2+</sup>) INCLUDING LACTATED<br/>RINGER’S SOLUTION AND<br/>HARTMANN’S SOLUTION.</paragraph>
                  <paragraph>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <br/>One Single-Dose Vial –<br/>Discard Unused Portion</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L84b37de7-e302-4ccc-b931-30333f7c1f9d"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230703"/>
               <component>
                  <observationMedia ID="L84b37de7-e302-4ccc-b931-30333f7c1f9d">
                     <text>carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Fig 1-carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>